Clinical Trials

• IMPAACT 2034 - Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of

  Study Location: India

  Eligibility: Ages Eligible for Study: up to 17 Years (Child ) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No

  Enrollment:

  Read More

• A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin,

  Study Location: India

  Eligibility: Target Participant Age 15 years and older Definite, probable, or possible TBM diagnosis from testing performed as part of...

  Enrollment:

  Read More

• Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to

  Study Location: India

  Eligibility: Adult, Pediatric, Household contacts

  Enrollment:

  Read More

• ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients with COVID-19 (Adapt Out COVID)

  Study Location: BaltimoreIndia

  Eligibility: Adults

  Enrollment:

  Read More

• P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and

  Study Location: BaltimoreIndia

  Eligibility: Preg/postpartum women. Infants

  Enrollment:

  Read More

• The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and

  Study Location: India

  Eligibility: Pediatrics

  Enrollment:

  Read More

• Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)

  Study Location: BaltimoreIndia

  Eligibility: Adults, adolescents

  Enrollment:

  Read More

• A5300B/I2003B/PHOENIX, Protecting Households On Exposure to Newly Diagnosed Index

  Study Location: India

  Eligibility: Men and women age greater than or equal to 18 year

  Enrollment:

  Read More

• P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus

  Study Location: India

  Eligibility: HIV-1-infected pregnant women initiating antiretroviral therapy at 14-28 weeks gestation, and their infants

  Enrollment:

  Read More

• P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety,

  Study Location: India

  Eligibility: HIV-infected and HIV-uninfected infants, children, and adolescents less than 18 years of age with confirmed or probable MDR-TB.

  Enrollment:

  Read More
•  1 2 3 >  Last ›